VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium
Part of paid clinical trials in Duarte, California.
- Sponsor
- National Cancer Institute (NCI)
- Study ID
- NCT00407485
- Phase
- PHASE2
- Status
- Completed
Conditions
- Adenocarcinoma of the Bladder
- Distal Urethral Cancer
- Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
- Proximal Urethral Cancer
- Recurrent Bladder Cancer
- Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
- Recurrent Urethral Cancer
- Squamous Cell Carcinoma of the Bladder
- Stage III Bladder Cancer
- Stage III Urethral Cancer
- Stage IV Bladder Cancer
- Transitional Cell Carcinoma of the Bladder
- Urethral Cancer Associated With Invasive Bladder Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- ziv-aflibercept — BIOLOGICALGiven IV
- pharmacological study — OTHERCorrelative studies
Study Details
This phase II trial is studying the side effects and how well VEGF Trap works in treating patients with recurrent, locally advanced, or metastatic cancer of the urothelium. VEGF Trap may stop the growth of tumor cells by blocking blood flow to the tumor.
Key Dates
- Start date
- Nov 30, 2006
- Status verified
- Oct 2013
- Primary completion
- Apr 30, 2010
- Completion
- Apr 30, 2014
Study Design
- Enrollment
- 22 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment (ziv-aflibercept)Patients receive 4 mg/kg VEGF Trap IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
Primary Outcome Measure
Tumor Response Rate [ Time Frame: From the start of the treatment until disease progression or recurrence, assessed up to 4 years ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| City of Hope | Duarte | California | 91010 | - |
Find similar trials in Duarte, CA
By research site
Related Studies
- Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)PHASE2 · Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...PHASE2 · Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2Recruiting · University of Washington · Tampa, Florida